ClinicalTrials.gg

Program

HRS-5346

A development code. Also written as “MK-7262” and “HRS-5346 tablets”.

In Jiangsu HengRui Medicine's pipeline, Lp(a). Its studies are led by 2 companies.

Furthest: phase 2, since Feb 4, 20256 company-led studies, 3 open or runningLicense: Hengrui → Merck, Mar 2025Next primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine42 open or runningphase 2since Feb 4, 2025May 28, 2024Feb 2027phase 2 · NCT07767513
Merck21 open or runningphase 2since May 22, 2026May 22, 2026Oct 12, 2027phase 2 · NCT07614984
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5346, phase 2, as of Jul 31, 2026 (source).
  • Named in Merck’s own pipeline as MK-7262, phase 2, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2024First study: phase 1 study in Lipoprotein Disorder DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06441227 · 71 enrolled · China
  2. Feb 4, 2025Phase 2 study in Treatment of Lipoprotein DisorderJiangsu HengRui Medicine · NCT06816264 · 120 enrolled · China
  3. May 22, 2026Merck's first study: phase 2 study in Lipoprotein(a)New to MerckMerck · NCT07614984 · 750 planned · United States, Canada, Colombia and more
  4. May 27, 2026Phase 1 study in HealthyMerck · NCT07619443 · 30 enrolled · United States
  5. Aug 4, 2026Phase 1 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07752069 · 50 planned · China
  6. Aug 12, 2026Phase 2 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07767513 · 60 planned · China

Ahead

  1. Feb 2027Primary completion: phase 2 study in Lipoprotein DisorderJiangsu HengRui Medicine · NCT07767513
  2. Oct 12, 2027Primary completion: phase 2 study in Lipoprotein(a)Merck · NCT07614984

TargetBeta

“Lp(a)”the company's pipeline, read by Claude · source

Other programs on LPA

ProgramCompanyFurthest phaseStudies
DII235Novartisphase 21
JAR-2203rulebeijing-jiake-ruikang-pharmaceutical-technology-co-ltdphase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07767513Lipoprotein Disorder · China2RecruitingJiangsu HengRui MedicineFeb 202760
NCT07752069Lipoprotein Disorder · China1Not yet recruitingJiangsu HengRui MedicineSep 202650
NCT07619443Healthy · United States1CompletedMerckSep 5, 202630
NCT07614984Lipoprotein(a) · United States, Canada, Colombia and more2RecruitingMerckOct 12, 2027750
NCT06816264Treatment of Lipoprotein Disorder · China2CompletedJiangsu HengRui MedicineSep 29, 2025120
NCT06441227Lipoprotein Disorder Disease · China1CompletedJiangsu HengRui MedicineJan 9, 202571

How it is read

Names in the registry

  • “HRS-5346”, 5 entries
  • “MK-7262”, 2 entries
  • “HRS-5346 tablets”, 1 entry

Codes read as this program: HRS5346, MK7262.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.